Trial Profile
A pivotal trial of Cabiralizumab for Pigmented villonodular synovitis (PVNS)
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 14 Aug 2017
Price :
$35
*
At a glance
- Drugs Cabiralizumab (Primary)
- Indications Pigmented villonodular synovitis
- Focus Registrational; Therapeutic Use
- Sponsors Five Prime Therapeutics
- 14 Aug 2017 New trial record